Persistent Asset Partners’s SAB Biotherapeutics SABS Stock Holding History
Bought
Maintained
Sold
Other funds holding SABS
Persistent Asset Partners's SABS Position: Q3 2026 in Review
Persistent Asset Partners sold out of SAB Biotherapeutics (SABS) in Q3 2026, closing a stake of 25,400 shares — an estimated $99.1K sold.
Persistent Asset Partners first reported a position in SABS in Q4 2025 and held it in 3 quarters. The position peaked at $267K in Q1 2026. 100 funds tracked by Wall St. Rank hold SABS as of Q3 2026.
- Persistent Asset Partners reported no remaining SAB Biotherapeutics position as of Q3 2026 after selling out during the quarter.
- Persistent Asset Partners sold 25,400 SAB Biotherapeutics shares in Q3 2026, an estimated $99.1K.
- Persistent Asset Partners first reported a position in SAB Biotherapeutics in Q4 2025 and held it in 3 quarters.
- Persistent Asset Partners's SAB Biotherapeutics position peaked at $267K in Q1 2026.
- 100 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q3 2026.
Based on Persistent Asset Partners's 13F filing for Q3 2026, filed 13 Nov 2026.